Home

Kursmål

https://www.marketscreener.com/quote/stock/GUBRA-A-S-152341330/news/Kempen-raises-target-price-for-Gubra-to-DKK-1-200-800-reiterates-Buy-BN-48362744/

https://www.marketscreener.com/quote/stock/GUBRA-A-S-152341330/news/ABG-Sundal-Collier-raises-target-price-for-Gubra-to-DKK-800-600-reiterates-Buy-48376998/

News

December 2024

https://ekstrabladet.dk/penge/dansk-biotekkomet-lander-kaempe-aftale-paa-50-mio.-dollars/10482761

har landet en aftale, der kan sikre selskabet mere end 50 millioner dollars

https://www.euroinvestor.dk/nyheder/markedsanalytiker-er-gubra-den-naeste-vaegttabsblockbuster

R&D-pipeline med fokus på peptide-baserede lægemidler, herunder vægttabsmidler

https://www.marketscreener.com/quote/stock/GUBRA-A-S-152341330/news/Gubra-in-collaboration-with-Amylyx-to-develop-long-acting-GLP-1-antagonists-48663732/

Danish biotech company Gubra has partnered with Amylyx Pharmaceuticals to develop a novel long-acting GLP-1 receptor antagonist, according to a press release.

"We are pleased to partner with Amylyx to advance research in GLP-1 receptor antagonism. This collaboration and development agreement is an example of leading pharmaceutical companies partnering with us for our machine learning-based peptide drug discovery platform. This is further proof that our streaMLine platform can be used to develop peptide drug candidates for a very wide range of diseases", says CEO Henrik Blou.

=============== efterår 2024 ===================

https://ekstrabladet.dk/penge/glem-wegovy-her-er-fremtidens-fedmeraketter/10460263

"Ifølge professoren er Novo længst med den nye udvikling - stærkt forfulgt at danske biotekselskaber som Zealand Pharma og Gubra"

https://borsen.dk/overblik/virksomhed/gubra

https://ugebrev.dk/virksomhed/gubra/

https://www.berlingske.dk/emne/gubra